Literature DB >> 15867490

Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection.

Camilla S Graham1, Annalee Wells, Tun Liu, Kenneth E Sherman, Marion Peters, Raymond T Chung, Atul K Bhan, Janet Andersen, Margaret James Koziel.   

Abstract

OBJECTIVE: To test the hypothesis that antigen-specific interferon (IFN)gamma responses are correlated with milder liver disease in subjects coinfected with HIV-1 and hepatitis C virus (HCV).
DESIGN: Cellular immune responses were studied in a cohort with HIV/HCV coinfection (n = 107) who underwent liver biopsy.
METHODS: We measured HCV-specific and recall responses in peripheral blood mononuclear cells using IFNgamma and interleukin (IL)-10 ELISpots, and correlated these immune responses with liver histology. The relationship of immunologic, virologic and clinical variables to inflammation and fibrosis was modeled using recursive partitioning.
RESULTS: There were significant negative correlations between inflammatory scores and IFNgamma production in response to the HCV proteins core, NS5 and summed HCV responses. Lower fibrosis scores were also correlated with higher IFNgamma production in response to NS5 and summed HCV proteins. Higher IFNgamma production in response to Candida was significantly associated with lower inflammatory and fibrosis scores. In multivariable models, factors associated with severe fibrosis were lower IFNgamma responses to Candida and summed HCV proteins. Factors associated with severe inflammation were detectable HIV viral load and lower HCV viral load, while predictors of mild inflammation included undetectable HIV viral load and higher IFNgamma response to Candida.
CONCLUSIONS: In this cohort of subjects coinfected with HIV and HCV, antigen-specific IFNgamma responses are correlated with milder inflammation and fibrosis. Immunological responses best predicted severity of fibrosis, while clinical variables and recall antigen responses best predicted severity of inflammation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15867490      PMCID: PMC4050654          DOI: 10.1097/01.aids.0000168970.80551.3d

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  24 in total

Review 1.  Fibrotic disease and the T(H)1/T(H)2 paradigm.

Authors:  Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

2.  Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

Authors:  M E Cramp; S Rossol; S Chokshi; P Carucci; R Williams; N V Naoumov
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

Review 3.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

4.  Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.

Authors:  Y Benhamou; M Bochet; V Di Martino; F Charlotte; F Azria; A Coutellier; M Vidaud; F Bricaire; P Opolon; C Katlama; T Poynard
Journal:  Hepatology       Date:  1999-10       Impact factor: 17.425

5.  Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection.

Authors:  Cheryl L Day; Georg M Lauer; Gregory K Robbins; Barbara McGovern; Alysse G Wurcel; Rajesh T Gandhi; Raymond T Chung; Bruce D Walker
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

6.  Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response.

Authors:  Kazushi Sugimoto; Jason Stadanlick; Fusao Ikeda; Colleen Brensinger; Emma E Furth; Harvey J Alter; Kyong-Mi Chang
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

7.  Partitioning methods for classification and decision making in medicine.

Authors:  R J Marshall
Journal:  Stat Med       Date:  1986 Sep-Oct       Impact factor: 2.373

8.  Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV.

Authors:  Camilla S Graham; Michael Curry; Qi He; Nezam Afdhal; David Nunes; Catherine Fleming; Robert Horsburgh; Donald Craven; Kenneth E Sherman; Margaret James Koziel
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

9.  Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

Authors:  Raymond T Chung; Janet Andersen; Paul Volberding; Gregory K Robbins; Tun Liu; Kenneth E Sherman; Marion G Peters; Margaret J Koziel; Atul K Bhan; Beverly Alston; Dodi Colquhoun; Tom Nevin; George Harb; Charles van der Horst
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

10.  Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis.

Authors:  Sanaa M Kamal; Camilla S Graham; Qi He; Leonardo Bianchi; Ahmed A Tawil; Jens W Rasenack; Khalifa A Khalifa; Mahmoud M Massoud; Margaret J Koziel
Journal:  J Infect Dis       Date:  2004-03-12       Impact factor: 5.226

View more
  12 in total

1.  Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection.

Authors:  Camilla S Graham; Annalee Wells; Tun Liu; Kenneth E Sherman; Marion Peters; Raymond T Chung; Atul K Bhan; Janet Andersen; Margaret James Koziel
Journal:  AIDS       Date:  2006-02-14       Impact factor: 4.177

Review 2.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

Review 3.  Substance abuse, HIV-1 and hepatitis.

Authors:  Nirzari Parikh; Michael R Nonnemacher; Vanessa Pirrone; Timothy Block; Anand Mehta; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2012-10       Impact factor: 1.581

4.  Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients.

Authors:  M K Jain; B Adams-Huet; D Terekhova; L E Kushner; R Bedimo; X Li; M Holodniy
Journal:  J Viral Hepat       Date:  2014-02-09       Impact factor: 3.728

5.  Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses.

Authors:  Nadia Alatrakchi; Camilla S Graham; Hans J J van der Vliet; Kenneth E Sherman; Mark A Exley; Margaret James Koziel
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

6.  Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis.

Authors:  David E Kaplan; Fusao Ikeda; Yun Li; Nobuhiro Nakamoto; Sutharsan Ganesan; Mary E Valiga; Frederick A Nunes; K Rajender Reddy; Kyong-Mi Chang
Journal:  J Hepatol       Date:  2008-03-07       Impact factor: 25.083

Review 7.  Coinfection with HIV-1 and HCV--a one-two punch.

Authors:  Arthur Y Kim; Raymond T Chung
Journal:  Gastroenterology       Date:  2009-06-21       Impact factor: 22.682

8.  Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection.

Authors:  Arthur Y Kim; Julian Schulze zur Wiesch; Thomas Kuntzen; Joerg Timm; Daniel E Kaufmann; Jared E Duncan; Andrea M Jones; Alysse G Wurcel; Benjamin T Davis; Rajesh T Gandhi; Gregory K Robbins; Todd M Allen; Raymond T Chung; Georg M Lauer; Bruce D Walker
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

9.  Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review).

Authors:  José Veríssimo Fernandes; Thales Allyrio Araújo DE Medeiros Fernandes; Jenner Chrystian Veríssimo DE Azevedo; Ricardo Ney Oliveira Cobucci; Maria Goretti Freire DE Carvalho; Vania Sousa Andrade; Josélio Maria Galvão DE Araújo
Journal:  Oncol Lett       Date:  2015-01-16       Impact factor: 2.967

10.  Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients.

Authors:  Lauren E Kushner; Aaron M Wendelboe; Laura C Lazzeroni; Aarthi Chary; Mark A Winters; Anu Osinusi; Shyam Kottilil; Michael A Polis; Mark Holodniy
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.